Biologicals in gastroenterology: TNF-blockers

被引：1

作者：

Scharl, M. ^{[1
]}

Rogler, G. ^{[1
]}

机构：

[1] Univ Spital Zurich, Dept Innere Med, Klin Gastroenterol & Hepatol, CH-8091 Zurich, Switzerland

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2010年 / 135卷 / 45期

关键词：

inflammatory bowel disease; Crohn's disease; ulcerative colitis; TNF-blocker; biologicals; CROHNS-DISEASE; INFLIXIMAB MAINTENANCE; EPISODIC TREATMENT; ADALIMUMAB; THERAPY; EFFICACY; SAFETY; INFECTIONS; ANTIBODY;

D O I：

10.1055/s-0030-1267508

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

TNF-blockers represent a well accepted therapeutic option in the treatment of inflammatory bowel disease. Though they are successfully used in many patients, they can also exert severe side effects, such as infectious diseases. Therefore, a careful review of the patient history as well as a continuous evaluation of the patients state of health is crucial before starting an anti-TNF therapy during the therapeutic treatment. In addition, we review also the possibilities by loss of efficacy of an anti-TNF therapy, such as dose increase or re-induction therapy. © 2010 Georg Thieme Verlag KG Stuttgart · New York.

引用

下载

页码：2243 / 2252

页数：10

共 50 条

[41] Evolution of biologicals in inflammation medicine - Biosimilars in gastroenterology, rheumatology and dermatology
Schreiber, S.
Luger, T.
Mittendorf, T.
Mrowietz, U.
Mueller-Ladner, U.
Schroeder, J.
Stallmach, A.
Bokemeyer, B.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 (47) : 2399 - 2404
[42] Cost per unit of radiographic outcome for TNF-blockers: Effect of disease duration, prior methotrexate failure, concomitant methotrexate use, and markers of inflammation
Yocum, DE
Bala, M
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 524 - 524
[43] STEP-DOWN STRATEGY OF SPACING TNF-BLOCKERS INJECTIONS FOR ESTABLISHED RHEUMATOID ARTHRITIS IN REMISSION: A COST-UTILITY ANALYSIS BASED ON THE STRASS TRIAL
Vanier, A.
Tubach, F.
Alfaiate, T.
Mariette, X.
Fautrel, B.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 178 - 178
[44] Non-TNF-Biologika in der TherapieNon-TNF biologicals in therapy
J. Wollenhaupt
G.-R. Burmester
Zeitschrift für Rheumatologie, 2010, 69 : 579 - 580
[45] Autoantibodies and thrombophilia in RA:: TNFα and TNFα blockers
Ferraccioli, GF
Gremese, E
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (06) : 613 - 615
[46] Switching biologicals:: Switching TNFα antagonists in psoriasis treatment
Schmitt-Egenolf, Marcus
DERMATOLOGY, 2008, 216 (04) : 281 - 282
[47] Introduction to the topic: Non-TNF biologicals in therapy
Wollenhaupt, J.
Burmester, G. -R.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2010, 69 (07): : 579 - 580
[48] CHANGE OF ASDAS OVER 3 MONTHS IS A GOOD PREDICTIVE FACTOR FOR IMPROVEMENT OF METROLOGY INDEX AFTER LONG-TERM TREATMENT WITH TNF-BLOCKERS IN ANKYLOSING SPONDYLITIS
Nam, E. J.
Kwon, S. H.
Eun, J. S.
Kim, N. R.
Kang, Y. M.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 758 - 758
[49] PROFILING OF SYSTEMIC IMMUNE RESPONSES IN AXIAL SPONDYLOARTHRITIS PATIENTS REVEALS STRIKINGLY DISTINCT CELLULAR AND MOLECULAR MECHANISMS OF ACTION OF IL-17A INHIBITORS AND TNF-BLOCKERS
Rosine, N.
Koturan, S.
Guillemot, V.
Leloup, C.
Veress, F.
Stephen, T.
Yahia, H.
Sellam, J.
Berenbaum, F.
Pietrosemoli, N.
Bianchi, E.
Richard, C. Miceli
Rogge, L.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 881 - 881
[50] Profiling of Systemic Immune Responses in Axial Spondyloarthritis Patients Reveals Strikingly Distinct Cellular and Molecular Mechanisms of Action of IL-17A Inhibitors and TNF-Blockers
Rosine, Nicolas
Koturan, Surya
Guillemot, Vincent
Leloup, Claire
Veress, Fanni
Stephen, Tharshana
Yahia-Cherbal, Hanan
Sellam, Jeremie
Berenbaum, Francis
Pietrosemoli, Natalia
Bianchi, Elisabetta
MIceli, Corinne
Rogge, Lars
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1109 - 1111

← 1 2 3 4 5 →